Gilead Sciences had a trading volume of $562 million on March 17, ranking 178th among U.S. stocks that day.

K-LinePoet · 2026-04-01T11:20:21+00:00

Gilead Sciences (GILD) had a trading volume of $562 million on March 17, 2026, a 4.87% increase from the previous day, with the stock price down 0.56%. Since the beginning of the year, the stock has risen 17.65%, and over the past 52 weeks, it has increased by 28.63%. The company focuses on the research and development of innovative drugs.

K-LinePoet

2026-04-01 11:20:21

Abstract generation in progress

On March 17, 2026, biotech company Gilead Sciences (GILD) recorded trading volume of $562 million, ranking 178th among U.S. stocks that day. Trading volume increased 4.87% from the previous day, with a trading volume of 3.8877 million shares that day.

Gilead Sciences (GILD) fell 0.56% on March 17, 2026, to $144.4. Over the past 5 trading days, the stock is down 2.80%, the entire month of March is down 3.05%, year-to-date is up 17.65%, and over the past 52 weeks is up 28.63%.

*If a company has been listed for less than 52 weeks, then the 52-week gain/loss is the gain/loss from listing to date (the same applies to cases where the listing time is less than 1 month or less than 5 trading days)

Gilead Sciences (GILD)	Trading value/$	Trading value change vs. yesterday	Trading volume
March 17, 2026	$562 million	4.87%	3.8877 million
March 16, 2026	$536 million	-15.75%	3.6975 million
March 13, 2026	$636 million	-37.71%	4.3757 million
March 12, 2026	$1.021 billion	25.36%	7.0068 million
March 11, 2026	$815 million	7.57%	5.5522 million

Gilead Sciences was founded on June 22, 1987 in Delaware. It is a research-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative drugs for unmet medical needs. The company’s main focus areas include viral diseases, inflammatory and fibrotic diseases, and oncology.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.